---
title: "ResMed Inc. (RMD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RMD.US.md"
symbol: "RMD.US"
name: "ResMed Inc."
industry: "Health Care Equipment"
datetime: "2026-05-20T01:56:24.411Z"
locales:
  - [en](https://longbridge.com/en/quote/RMD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RMD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RMD.US.md)
---

# ResMed Inc. (RMD.US)

## Company Overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.resmed.com](https://www.resmed.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: B (0.28)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 8 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 10.28% |  |
| Net Profit YoY | 15.71% |  |
| P/B Ratio | 4.58 |  |
| Dividend Ratio | 1.18% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 29740245564.15 |  |
| Revenue | 5537789000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 25.25% | A |
| Profit Margin | 27.44% | A |
| Gross Margin | 62.79% | A |
| Revenue YoY | 10.28% | B |
| Net Profit YoY | 15.71% | C |
| Total Assets YoY | 16.09% | B |
| Net Assets YoY | 17.05% | B |
| Cash Flow Margin | 124.38% | B |
| OCF YoY | 10.28% | B |
| Turnover | 0.68 | B |
| Gearing Ratio | 26.10% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - ResMed Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "10.28%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "15.71%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.58",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.18%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "29740245564.15",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5537789000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "25.25%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "27.44%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "62.79%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "10.28%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "15.71%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "16.09%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "17.05%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "124.38%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "10.28%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.68",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.10%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 19.92 | 15/183 | 28.56 | 25.97 | 24.42 |
| PB | 4.66 | 97/183 | 6.73 | 6.10 | 5.74 |
| PS (TTM) | 5.47 | 97/183 | 7.70 | 7.10 | 6.68 |
| Dividend Yield | 1.16% | 12/183 | 0.94% | 0.88% | 0.81% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **20**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 40% |
| Overweight | 3 | 15% |
| Hold | 7 | 35% |
| Sell | 1 | 5% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 207.78 |
| Highest Target | 340.00 |
| Lowest Target | 180.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RMD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RMD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RMD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RMD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**